Canada Myasthenia Gravis Treatment Market Size & Outlook

The myasthenia gravis treatment market in Canada is expected to reach a projected revenue of US$ 69.2 million by 2032. A compound annual growth rate of 3.3% is expected of Canada myasthenia gravis treatment market from 2022 to 2032.
Revenue, 2021 (US$M)
$48.6
Forecast, 2032 (US$M)
$190.5
CAGR, 2022 - 2032
13.2%
Report Coverage
Canada

Canada myasthenia gravis treatment market highlights

  • The Canada myasthenia gravis treatment market generated a revenue of USD 48.6 million in 2021 and is expected to reach USD 190.5 million by 2032.
  • The Canada market is expected to grow at a CAGR of 13.2% from 2022 to 2032.
  • In terms of segment, monoclonal antibodies was the largest revenue generating treatment type in 2021.
  • Monoclonal Antibodies is the most lucrative treatment type segment registering the fastest growth during the forecast period.


Myasthenia gravis treatment market data book summary

Market revenue in 2021USD 48.6 million
Market revenue in 2032USD 190.5 million
Growth rate13.2% (CAGR from 2021 to 2032)
Largest segmentMonoclonal antibodies
Fastest growing segmentMonoclonal Antibodies
Historical data2018 - 2020
Base year2021
Forecast period2022 - 2032
Quantitative unitsRevenue in USD million
Market segmentationCholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy
Key market players worldwideAstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd


Other key industry trends

  • In terms of revenue, Canada accounted for 2.8% of the global myasthenia gravis treatment market in 2021.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2032.
  • In North America, U.S. myasthenia gravis treatment market is projected to lead the regional market in terms of revenue in 2032.
  • Canada is the fastest growing regional market in North America and is projected to reach USD 190.5 million by 2032.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Myasthenia Gravis Treatment Market Companies

Name Profile # Employees HQ Website

Canada myasthenia gravis treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.


Monoclonal antibodies was the largest segment with a revenue share of 46.09% in 2021. Horizon Databook has segmented the Canada myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.


The growth of Canada myasthenia gravis treatment market can be attributed to high healthcare expenditure and favorable reimbursement policies in the country, leading to higher access to innovative diagnosis and treatment therapies.

For instance, Immunovant, a U.S.-based company, is expected to announce data from its Phase 2a ASCEND MG clinical trial study, which is inspecting tolerability and safety of IMVT1401 in MG patients. The company is still recruiting participants at multiple sites in the U.S. & Canada and is expected to enroll 21 MG patients.

Moreover, rising public-private initiatives and growing investments are among factors likely to drive the market. The Myasthenia Gravis Society of Canada is among organizations providing dedicated services to improve the quality of life and deliver sophisticated medical care to MG patients.

Reasons to subscribe to Canada myasthenia gravis treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Canada myasthenia gravis treatment market databook

  • Our clientele includes a mix of myasthenia gravis treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Canada myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Canada myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Canada myasthenia gravis treatment market size, by treatment type, 2018-2032 (US$M)

Canada Myasthenia Gravis Treatment Market Outlook Share, 2021 & 2032 (US$M)

Canada myasthenia gravis treatment market size, by treatment type, 2018-2032 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more